As we reported earlier, the Australian Technical Advisory Group on Immunisation (ATAGI) has approved the Novavax COVID-19 vaccine to be included in Australia’s rollout program.
ATAGI has recommended Novavax be given in two doses, at least three weeks apart.
Australia has purchased 51 million doses of the Novavax COVID-19 vaccine with samples to arrive early next month to enable TGA batch testing, the Health Minister said in a news release.
Subject to successful TGA batch testing, the Novavax vaccine will be available to be administered from the week of February 21.
Australians wanting the Novavax vaccine will be able to access it through general practices, community pharmacies, Aboriginal Community Controlled Health Services, Commonwealth vaccination centres, and state and territory clinics.
Novavax is only approved by the TGA for use in a primary course of vaccination with studies for its use as a booster and in paediatric patients are ongoing.
Novavax is the fourth COVID-19 vaccine to be approved for use in Australia after Vaxzevria (AstraZeneca), Spikevax (Moderna), and Comirnaty (Pfizer).
Be the first to comment